Cargando…

Discrepant Effects of Human Interferon-gamma on Clinical and Immunological Disease Parameters in a Novel Marmoset Model for Multiple Sclerosis

The core pathogenic process in the common marmoset model of multiple sclerosis (MS) is the activation of memory-like T cells specific for peptide 34 to 56 derived from the extracellular domain of myelin/oligodendrocyte glycoprotein (MOG(34-56)). Immunization with MOG(34-56) in incomplete Freund’s ad...

Descripción completa

Detalles Bibliográficos
Autores principales: Jagessar, S. Anwar, Gran, Bruno, Heijmans, Nicole, Bauer, Jan, Laman, Jon D., ‘t Hart, Bert A., Constantinescu, Cris S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3280389/
https://www.ncbi.nlm.nih.gov/pubmed/22012268
http://dx.doi.org/10.1007/s11481-011-9320-5
_version_ 1782223824091086848
author Jagessar, S. Anwar
Gran, Bruno
Heijmans, Nicole
Bauer, Jan
Laman, Jon D.
‘t Hart, Bert A.
Constantinescu, Cris S.
author_facet Jagessar, S. Anwar
Gran, Bruno
Heijmans, Nicole
Bauer, Jan
Laman, Jon D.
‘t Hart, Bert A.
Constantinescu, Cris S.
author_sort Jagessar, S. Anwar
collection PubMed
description The core pathogenic process in the common marmoset model of multiple sclerosis (MS) is the activation of memory-like T cells specific for peptide 34 to 56 derived from the extracellular domain of myelin/oligodendrocyte glycoprotein (MOG(34-56)). Immunization with MOG(34-56) in incomplete Freund’s adjuvant is a sufficient stimulus for in vivo activation of these T cells, together with the induction of MS-like disease and CNS pathology. Ex vivo functional characteristics of MOG(34-56) specific T cells are specific cytolysis of peptide pulsed target cells and high IL-17A production. To indentify possible functions in this new model of T helper 1 cells, which play a central pathogenic role in MS models induced with complete Freund’s adjuvant, we tested the effect of human interferon-γ (IFNγ) administration during disease initiation of the disease (day 0–25) and around the time of disease expression (psd 56–81). The results show a clear modulatory effect of early IFNγ treatment on humoral and cellular autoimmune parameters, but no generalized mitigating effect on the disease course. These results argue against a prominent pathogenic role of T helper 1 cells in this new marmoset EAE model. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s11481-011-9320-5) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-3280389
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-32803892012-03-01 Discrepant Effects of Human Interferon-gamma on Clinical and Immunological Disease Parameters in a Novel Marmoset Model for Multiple Sclerosis Jagessar, S. Anwar Gran, Bruno Heijmans, Nicole Bauer, Jan Laman, Jon D. ‘t Hart, Bert A. Constantinescu, Cris S. J Neuroimmune Pharmacol Original Article The core pathogenic process in the common marmoset model of multiple sclerosis (MS) is the activation of memory-like T cells specific for peptide 34 to 56 derived from the extracellular domain of myelin/oligodendrocyte glycoprotein (MOG(34-56)). Immunization with MOG(34-56) in incomplete Freund’s adjuvant is a sufficient stimulus for in vivo activation of these T cells, together with the induction of MS-like disease and CNS pathology. Ex vivo functional characteristics of MOG(34-56) specific T cells are specific cytolysis of peptide pulsed target cells and high IL-17A production. To indentify possible functions in this new model of T helper 1 cells, which play a central pathogenic role in MS models induced with complete Freund’s adjuvant, we tested the effect of human interferon-γ (IFNγ) administration during disease initiation of the disease (day 0–25) and around the time of disease expression (psd 56–81). The results show a clear modulatory effect of early IFNγ treatment on humoral and cellular autoimmune parameters, but no generalized mitigating effect on the disease course. These results argue against a prominent pathogenic role of T helper 1 cells in this new marmoset EAE model. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s11481-011-9320-5) contains supplementary material, which is available to authorized users. Springer US 2011-10-20 2012 /pmc/articles/PMC3280389/ /pubmed/22012268 http://dx.doi.org/10.1007/s11481-011-9320-5 Text en © The Author(s) 2011 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
spellingShingle Original Article
Jagessar, S. Anwar
Gran, Bruno
Heijmans, Nicole
Bauer, Jan
Laman, Jon D.
‘t Hart, Bert A.
Constantinescu, Cris S.
Discrepant Effects of Human Interferon-gamma on Clinical and Immunological Disease Parameters in a Novel Marmoset Model for Multiple Sclerosis
title Discrepant Effects of Human Interferon-gamma on Clinical and Immunological Disease Parameters in a Novel Marmoset Model for Multiple Sclerosis
title_full Discrepant Effects of Human Interferon-gamma on Clinical and Immunological Disease Parameters in a Novel Marmoset Model for Multiple Sclerosis
title_fullStr Discrepant Effects of Human Interferon-gamma on Clinical and Immunological Disease Parameters in a Novel Marmoset Model for Multiple Sclerosis
title_full_unstemmed Discrepant Effects of Human Interferon-gamma on Clinical and Immunological Disease Parameters in a Novel Marmoset Model for Multiple Sclerosis
title_short Discrepant Effects of Human Interferon-gamma on Clinical and Immunological Disease Parameters in a Novel Marmoset Model for Multiple Sclerosis
title_sort discrepant effects of human interferon-gamma on clinical and immunological disease parameters in a novel marmoset model for multiple sclerosis
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3280389/
https://www.ncbi.nlm.nih.gov/pubmed/22012268
http://dx.doi.org/10.1007/s11481-011-9320-5
work_keys_str_mv AT jagessarsanwar discrepanteffectsofhumaninterferongammaonclinicalandimmunologicaldiseaseparametersinanovelmarmosetmodelformultiplesclerosis
AT granbruno discrepanteffectsofhumaninterferongammaonclinicalandimmunologicaldiseaseparametersinanovelmarmosetmodelformultiplesclerosis
AT heijmansnicole discrepanteffectsofhumaninterferongammaonclinicalandimmunologicaldiseaseparametersinanovelmarmosetmodelformultiplesclerosis
AT bauerjan discrepanteffectsofhumaninterferongammaonclinicalandimmunologicaldiseaseparametersinanovelmarmosetmodelformultiplesclerosis
AT lamanjond discrepanteffectsofhumaninterferongammaonclinicalandimmunologicaldiseaseparametersinanovelmarmosetmodelformultiplesclerosis
AT thartberta discrepanteffectsofhumaninterferongammaonclinicalandimmunologicaldiseaseparametersinanovelmarmosetmodelformultiplesclerosis
AT constantinescucriss discrepanteffectsofhumaninterferongammaonclinicalandimmunologicaldiseaseparametersinanovelmarmosetmodelformultiplesclerosis